CRDF — Cardiff Oncology Share News
0.000.00%
Last trade - 00:00- $70.58m
- $34.93m
- $0.59m
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering
Brief: Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting
Brief: Cardiff Oncology - Nms Informs Cardiff Oncology Of Agreement Termination On May 27, 2026
Cardiff Oncology Q1 net loss narrows as operating expenses fall
Brief: Cardiff Oncology Announces Key Leadership Appointments To Strengthen Executive Team For Next Phase Of Growth
U.S. STOCKS ON THE MOVE.-CoreWeave, Texas Instruments, Richtech Robotics
U.S. STOCKS ON THE MOVE-Sysco, Corning, HCA Healthcare
U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA Healthcare
Cardiff Oncology plunges after top executives step down
Cardiff Oncology posts smaller-than-expected Q3 loss
Brief: Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004)
Cardiff Oncology Q2 net loss widens
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Cardiff Oncology appoints Dr. Roger Sidhu as Chief Medical Officer
Brief: Cardiff Oncology Announces Positive Data From Investigator-Initiated Trial Of Onvansertib In Combination With Paclitaxel
Cardiff Oncology Inc reports results for the quarter ended March 31 - Earnings Summary